Valuation: ALLOVIRPAR

Market Cap 49.21M 42.78M 39.82M 36.56M 69.04M 4.7B 70.11M 469M 184M 2.34B 185M 181M 7.84B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -60.05M -55.89M -51.32M -96.91M -6.59B -98.41M -659M -259M -3.28B -259M -254M -11.01B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+0.86%
Current month-64.22%
Current year-64.22%
3 years 3.4
Extreme 3.4001
86.25
5 years 3.4
Extreme 3.4001
607.43
10 years 3.4
Extreme 3.4001
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -166M -154M -141M -267M -18.18B -271M -1.82B -713M -9.05B -715M -699M -30.34B -58.77M -51.09M -47.55M -43.66M -82.45M -5.61B -83.72M -561M -220M -2.79B -221M -216M -9.37B
Net Debt -157M -136M -127M -116M -220M -14.94B -223M -1.49B -586M -7.44B -588M -575M -24.94B -118M -103M -95.71M -87.87M -166M -11.29B -169M -1.13B -443M -5.62B -444M -434M -18.85B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
31/07/26 US$3.510 +0.86% 71,946
30/07/26 US$3.480 +2.35% 76,286
29/07/26 US$3.400 +1.80% 100,019
28/07/26 US$3.340 -6.70% 118,283
27/07/26 US$3.580 -4.02% 71,676
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock